Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 3/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751394 | 0.99 | CXCR5 (0.46) | CXCR5PSMB5UGCGPTGER4HDAC11 | |
| SCHEMBL1898861 | 0.90 | CXCR5 (0.47) | CXCR5PSMB5UGCGPTGER4HDAC11 | |
| SCHEMBL1900140 | 0.88 | CXCR5 (0.45) | CXCR5PSMB5UGCGPTGER4HDAC11 | |
| SCHEMBL1900536 | 0.88 | PSMB5 (0.48) | CXCR5PSMB5UGCGPTGER4CTSL | |
| SCHEMBL5747861 | 0.87 | BACE1 (0.37) | PSMB5UGCGPTGER4BACE1BACE2 | |
| SCHEMBL1900082 | 0.86 | PTGER4 (0.38) | CXCR5UGCGPTGER4HDAC11BACE1 | |
| SCHEMBL5754024 | 0.84 | SSTR4 (0.41) | UGCGPTGER4HDAC11BACE1BACE2 | |
| SCHEMBL5753364 | 0.83 | BACE1 (0.37) | CXCR5UGCGPTGER4BACE1BACE2 | |
| SCHEMBL5753540 | 0.83 | TRPV1 (0.41) | UGCG | |
| SCHEMBL1899579 | 0.82 | CTSL (0.40) | CXCR5PSMB5UGCGCTSLBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | CXCR5 4765/4885PSMB5 2181/4885UGCG 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.